

COVID-19 Clinical Studies Update

- **Completed recruitment of 100 positive COVID-19 cases in India**
- **Indian study expanded to 200 positive COVID-19 cases and scheduled to complete recruitment by end of November 2021**
- **US recruitment expected to complete in mid-December 2021**
- **ResApp to now commence analysing the data collected in India and the US, and is best positioned globally to deliver an instant smartphone-based screening test for COVID-19**

Brisbane, Australia, 26 October 2021 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that its Indian COVID-19 clinical study (ref ASX announcement 9 August 2021) has completed recruitment of over 100 COVID-19 positive patients ahead of time. Given the fast recruitment and the value of additional data, the study has been expanded to 200 positive cases and is expected to complete recruitment by the end of November 2021.

ResApp's Indian clinical trial partner, Triomics, is now recruiting participants at all three hospital sites in India. The increase in case numbers will provide for greater robustness and certainty in evaluating COVID-19 screening test algorithm candidates to give ResApp the highest chance of developing a truly accurate algorithm for COVID-19 screening.

ResApp is also recruiting patients in two US clinical studies (ref ASX announcements 11 March 2021 and 9 August 2021), with enrolment now expected to complete in mid-December. The combination of data from India and the US will be crucial to testing the robustness of the algorithms across population groups.

ResApp is uniquely positioned as the only company that has commercialised a regulatory-approved smartphone application that uses cough sounds to instantly diagnose acute respiratory disease. ResApp also maintains the only extensive library of cough sounds and clinical diagnoses from patients with other respiratory diseases collected prior to COVID-19, which ensures that a developed algorithm truly identifies COVID-19 and correctly excludes non-COVID-19-related respiratory infections.

CEO and Managing Director, Dr Tony Keating said: *"We are pleased to have reached our initial target recruitment for COVID-19 positive cases in India ahead of time. We now commence the important work of analysing the data collected in India and the US, and performing specific algorithm training and validation to build on the foundational algorithm work we've undertaken over the past few months. The development of an instant smartphone-based screening test for COVID-19 could revolutionise the way the world manages the virus."*

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.